CNBC's Jackie DeAngelis discusses the day's activity in the commodities markets. The global supply glut concerns continue, as WTI and Brent were both down on the day. Nat gas popped 7 percent as cold weather hit the midwest.
CNBC's Bob Pisani and Kenny Polcari of O'Neil Securities discuss today's market activity, including the impact of oil and the news out of Japan.
CNBC's Kate Rogers looks at today's biggest movers including DreamWorks trading down 14 percent and Hasbro up 4 percent.
Discussing the health of the global economy, with Anthony Chan, Chase; David Malpass, Encima Global; and CNBC's Rick Santelli.
"Street Signs" hosts Mandy Drury and Brian Sullivan look at 5 stocks with analyst recommendations, including a downgrade for Marriott, as well as Procter & Gamble.
CNBC's Bob Pisani explains how investors can take a bite out of the new Shanghai-Hong Kong stock exchange.
The FMHR traders reveal their final trades.
CNBC's Simon Hobbs reports on all the market moving events in Europe today, including the impact of Mario Draghi's statement where he said the ECB could buy government bonds.
Gene Munster, Piper Jaffray managing director, shares his thoughts on "Facebook at Work," and its impact to the social networks core business.
The S&P 500 has at least three more years of double-digit gains and could peak at 3,500 to 4,000, Fundstrat Global Advisors founder Tom Lee says.
Discussing which retail sectors stand to benefit from cheap gas, with Chris Christopher, IHS Global Insight economist.
CNBC's Bob Pisani discusses Japan's big GDP miss and takes a look at the stock link between Shanghai and Hong Kong.
Allergan chairman & CEO David Pyott, explains why Allergan never engaged Valeant Pharmaceuticals and what's next for the newly combined companies.
CNBC's Jim Cramer speaks to Brent Saunders, Actavis CEO, and David Pyott, Allergan chairman & CEO, about the growth and R&D budget of the combined companies going forward.
CNBC's David Faber speaks to David Pyott, Allergan chairman & CEO, and Brent Saunders, Actavis CEO about their deal worth roughly $66 billion and what it means for shareholders.
Allergan is getting bought by Actavis in a deal worth about $66 billion. CNBC's David Faber provides insight on the acquisition.
Halliburton has agreed to acquire Baker Hughes for $34.6 billion in cash and stock. CNBC's David Faber and Jim Cramer discusses if the deal will be cleared by regulators.
CNBC's Jim Cramer says the deal between Halliburton and Baker Hughes will likely work and why Halliburton shareholders may want to rethink selling at this point.
U.S. stock futures were under some pressure early today, following world markets lower as Japan's economy entered a technical recession. The Nikkei dropped nearly 3 percent overnight.
Mad Money host Jim Cramer thinks next week could depend on this one event